Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20130211.TNBC

— · D

8c31f729-f7a0-54be-8afb-3c8b27a8908f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HYPOXIA+0.530
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • NOTCH_SIGNALING+0.400
  • ANGIOGENESIS+0.350
  • GLYCOLYSIS+0.290
  • UV_RESPONSE_DN+0.290
  • WNT_BETA_CATENIN_SIGNALING+0.250
  • MYOGENESIS+0.230
  • TNFA_SIGNALING_VIA_NFKB+0.210
  • COAGULATION+0.190

Top 10 suppressed

  • BILE_ACID_METABOLISM-0.320
  • ESTROGEN_RESPONSE_EARLY-0.310
  • ESTROGEN_RESPONSE_LATE-0.310
  • ANDROGEN_RESPONSE-0.290
  • PEROXISOME-0.280
  • DNA_REPAIR-0.270
  • MYC_TARGETS_V1-0.250
  • OXIDATIVE_PHOSPHORYLATION-0.240
  • FATTY_ACID_METABOLISM-0.200
  • ALLOGRAFT_REJECTION-0.190

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-EW-A2FR-01A-11R-A21T-07
breast-umap@18
—C0.737
2MBCProject_0217_T1_RNA
breast-umap@18
—C0.730
3TCGA-D8-A27H-01A-11R-A16F-07
breast-umap@18
—E0.727
4SRR1313158
breast-umap@18
—D0.706
5TCGA-77-8008-01A-21R-2187-07
lung-landscapes@6
—cohortSQ10.705
6TCGA-D8-A142-01A-11R-A115-07
breast-umap@18
—E0.700
7TCGA-A7-A0DA-01A-31R-A115-07
breast-umap@18
—E0.699
8TCGA-A2-A4RX-01A-11R-A266-07
breast-umap@18
—D0.695
9SRR25043621
head-neck@1
——0.695
10TCGA-CN-6022-01A-21R-1686-07
head-neck@1
——0.693

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HYPOXIA0.530Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
NOTCH_SIGNALING0.400Inavolisib— uncovered
ANGIOGENESIS0.350Remibrutinib— uncovered
GLYCOLYSIS0.290Inavolisib— uncovered
UV_RESPONSE_DN0.290Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.250Inavolisib— uncovered
MYOGENESIS0.230Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.210Inavolisib— uncovered
COAGULATION0.190Binimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.170Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.170Idelalisib— uncovered
PANCREAS_BETA_CELLS0.160Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.150Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.150Idelalisib— uncovered
APICAL_JUNCTION0.140Inavolisib— uncovered
MITOTIC_SPINDLE0.130Inavolisib— uncovered
MTORC1_SIGNALING0.130Inavolisib— uncovered
KRAS_SIGNALING_UP0.100Inavolisib— uncovered